Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
Go back to Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema| (NASDAQ: PHVS) | Delayed: 38.00 +0.45 (1.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $37.55 | 52 Week High | $ | |||
| Open | $37.81 | 52 Week Low | $ | |||
| Day High | $38.93 | P/E | N/A | |||
| Day Low | $37.60 | EPS | $ | |||
| Volume | 1,136,858 | |||||
